The biotech sector just got the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence.
The stock closed up an astonishing 177%, and the implications stretch far beyond a single company. It was a landmark validation of an entire mRNA platform, and a potential turning point for cancer treatment itself.
